An ultra performance liquid chromatography-tandem MS assay for tamoxifen metabolites profiling in plasma: First evidence of 4′-hydroxylated metabolites in breast cancer patients

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 878, Issue 32, 2010, Pages 3402-3414

  Dahmane, E ^a,b   Mercier, T ^a   Zanolari, B ^a   Cruchon, S ^a   Guignard, N ^a   Buclin, T ^a   Leyvraz, S ^a   Zaman, K ^a   Csajka, C ^a,b   Decosterd, L A ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

4 Hydroxy N desmethyl tamoxifen; 4 Hydroxy tamoxifen; 4 Hydroxy N desmethyl tamoxifen (endoxifen); 4 Hydroxy tamoxifen; Breast cancer; N Desmethyl tamoxifen; Tamoxifen; Tandem mass spectrometry; Ultra performance liquid chromatography

Indexed keywords

ACTIVE METABOLITES; AMMONIUM FORMATE; ANALYTES; BREAST CANCER; CALIBRATION SAMPLES; CHROMATOGRAPHIC SEPARATIONS; CLINICAL EFFICACY; CLINICAL TRIAL; ENZYMES ACTIVITY; HYDROXYLATED METABOLITES; INDIVIDUAL VARIABILITY; INTERNAL STANDARDS; LOWER LIMITS; MATRIX; MATRIX EFFECTS; PLASMA CONCENTRATION; PLASMA LEVELS; POSITIVE MODE; PROTEIN PRECIPITATION; ROOM TEMPERATURE; SELECTED REACTION MONITORING; SHORT TERM STABILITY; TAMOXIFEN; TANDEM MASS SPECTROMETRY; TANDEM MS; TRIPLE-QUADRUPOLE MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; UPLC-MS/MS; WHOLE BLOOD;

ACETONITRILE; AMMONIUM COMPOUNDS; BIOMOLECULES; DEUTERIUM; ELECTROSPRAY IONIZATION; FORMIC ACID; HIGH PRESSURE LIQUID CHROMATOGRAPHY; LIQUIDS; MASS SPECTROMETRY; METABOLISM; METABOLITES; NITROGEN PLASMA; PHASE SEPARATION; PLASMA STABILITY;

CHROMATOGRAPHY;

4 HYDROXYN DESMETHYLTAMOXIFEN ETHYL D5; 4 HYDROXYNORTAMOXIFEN; 4 HYDROXYTAMOXIFEN; 4 HYDROXYTAMOXIFEN ETHYL D5; 4' HYDROXY N DESMETHYLTAMOXIFEN; 4' HYDROXYTAMOXIFEN; ACETONITRILE; ALPHA HYDROXYTAMOXIFEN; AMMONIUM FORMATE; DROLOXIFENE; FORMIC ACID; N DESMETHYLTAMOXIFEN ETHYL D5; NITROGEN; NORTAMOXIFEN; PROTEIN; TAMOXIFEN; TAMOXIFEN DERIVATIVE; TAMOXIFEN ETHYL D5; TAMOXIFEN N OXIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BLOOD; BLOOD SAMPLING; BREAST CANCER; CALIBRATION; CANCER PATIENT; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG METABOLISM; DRUG STABILITY; ELECTROSPRAY MASS SPECTROMETRY; ELUTION; EVAPORATION; FEMALE; FOOD AND DRUG ADMINISTRATION; HUMAN; HYDROXYLATION; MAJOR CLINICAL STUDY; MAXIMUM PLASMA CONCENTRATION; METABOLITE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PURIFICATION; QUADRUPOLE MASS SPECTROMETRY; REACTOR MONITORING; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ROOM TEMPERATURE; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CALIBRATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG STABILITY; FEMALE; HUMANS; HYDROXYLATION; LOGISTIC MODELS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TAMOXIFEN; TANDEM MASS SPECTROMETRY;

EID: 78649885424     PISSN: 15700232     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchromb.2010.10.027     Document Type: Article

References (67)

1. Jordan V.C. Steroids 2007, 72:829.
2. Osborne C.K. N. Engl. J. Med. 1998, 339:1609.
3. Lancet 1998, 351:1451. Early Breast Cancer Trialists' Collaborative Group.
4. Lancet 2005, 365:1687. Early Breast Cancer Trialists' Collaborative Group.
5. Goldhirsch A., Wood W.C., Gelber R.D., Coates A.S., Thurlimann B., Senn H.J. Ann. Oncol. 2007, 18:1133.
6. Jordan V.C. Nat. Rev. Drug Discov. 2003, 2:205.
7. Visvanathan K., Chlebowski R.T., Hurley P., Col N.F., Ropka M., Collyar D., Morrow M., Runowicz C., Pritchard K.I., Hagerty K., Arun B., Garber J., Vogel V.G., Wade J.L., Brown P., Cuzick J., Kramer B.S., Lippman S.M. J. Clin. Oncol. 2009, 27:3235.
8. Johnson M.D., Zuo H., Lee K.H., Trebley J.P., Rae J.M., Weatherman R.V., Desta Z., Flockhart D.A., Skaar T.C. Breast Cancer Res. Treat. 2004, 85:151.
9. Katzenellenbogen B.S., Norman M.J., Eckert R.L., Peltz S.W., Mangel W.F. Cancer Res. 1984, 44:112.
10. Stearns V., Johnson M.D., Rae J.M., Morocho A., Novielli A., Bhargava P., Hayes D.F., Desta Z., Flockhart D.A. J. Natl. Cancer Inst. 2003, 95:1758.
11. Lim Y.C., Desta Z., Flockhart D.A., Skaar T.C. Cancer Chemother. Pharmacol. 2005, 55:471.
12. Lim Y.C., Li L., Desta Z., Zhao Q., Rae J.M., Flockhart D.A., Skaar T.C. J. Pharmacol. Exp. Ther. 2006, 318:503.
13. Desta Z., Ward B.A., Soukhova N.V., Flockhart D.A. J. Pharmacol. Exp. Ther. 2004, 310:1062.
14. Goetz M.P., Kamal A., Ames M.M. Clin. Pharmacol. Ther. 2008, 83:160.
15. Wu X., Hawse J.R., Subramaniam M., Goetz M.P., Ingle J.N., Spelsberg T.C. Cancer Res. 2009, 69:1722.
16. Clarke R., Liu M.C., Bouker K.B., Gu Z., Lee R.Y., Zhu Y., Skaar T.C., Gomez B., O'Brien K., Wang Y., Hilakivi-Clarke L.A. Oncogene 2003, 22:7316.
17. Ring A., Dowsett M. Endocr. Relat. Cancer 2004, 11:643.
18. Borges S., Desta Z., Li L., Skaar T.C., Ward B.A., Nguyen A., Jin Y., Storniolo A.M., Nikoloff D.M., Wu L., Hillman G., Hayes D.F., Stearns V., Flockhart D.A. Clin. Pharmacol. Ther. 2006, 80:61.
19. Jin Y., Desta Z., Stearns V., Ward B., Ho H., Lee K.H., Skaar T., Storniolo A.M., Li L., Araba A., Blanchard R., Nguyen A., Ullmer L., Hayden J., Lemler S., Weinshilboum R.M., Rae J.M., Hayes D.F., Flockhart D.A. J. Natl. Cancer Inst. 2005, 97:30.
20. Gjerde J., Hauglid M., Breilid H., Lundgren S., Varhaug J.E., Kisanga E.R., Mellgren G., Steen V.M., Lien E.A. Ann. Oncol. 2008, 19:56.
21. Lim H.S., Ju Lee H., Seok Lee K., Sook Lee E., Jang I.J., Ro J. J. Clin. Oncol. 2007, 25:3837.
22. Goetz M.P., Rae J.M., Suman V.J., Safgren S.L., Ames M.M., Visscher D.W., Reynolds C., Couch F.J., Lingle W.L., Flockhart D.A., Desta Z., Perez E.A., Ingle J.N. J. Clin. Oncol. 2005, 23:9312.
23. Goetz M.P., Knox S.K., Suman V.J., Rae J.M., Safgren S.L., Ames M.M., Visscher D.W., Reynolds C., Couch F.J., Lingle W.L., Weinshilboum R.M., Fritcher E.G., Nibbe A.M., Desta Z., Nguyen A., Flockhart D.A., Perez E.A., Ingle J.N. Breast Cancer Res. Treat. 2007, 101:113.
24. Schroth W., Antoniadou L., Fritz P., Schwab M., Muerdter T., Zanger U.M., Simon W., Eichelbaum M., Brauch H. J. Clin. Oncol. 2007, 25:5187.
25. Schroth W., Goetz M.P., Hamann U., Fasching P.A., Schmidt M., Winter S., Fritz P., Simon W., Suman V.J., Ames M.M., Safgren S.L., Kuffel M.J., Ulmer H.U., Bolander J., Strick R., Beckmann M.W., Koelbl H., Weinshilboum R.M., Ingle J.N., Eichelbaum M., Schwab M., Brauch H. JAMA 2009, 302:1429.
26. Stearns V., Rae J. Expert Rev. Mol. Med. 2008, 10:e34.
27. Hoskins J., Carey L., McLeod H. Nat. Rev. Cancer 2009, 9:576.
28. Kelly C., Juurlink D., Gomes T., Duong-Hua M., Pritchard K., Austin P., Paszat L. BMJ 2010, 340:c693.
29. Andersohn F., Willich S. BMJ 2010, 340:c783.
30. Nowell S., Ahn J., Rae J., Scheys J., Trovato A., Sweeney C., MacLeod S., Kadlubar F., Ambrosone C. Breast Cancer Res. Treat. 2005, 91:249.
31. Wegman P., Vainikka L., Stål O., Nordenskjöld B., Skoog L., Rutqvist L., Wingren S. Breast Cancer Res. 2005, 7:R284.
32. Wegman P., Elingarami S., Carstensen J., Stål O., Nordenskjöld B., Wingren S. Breast Cancer Res. 2007, 9:R7.
33. Lash T., Lien E., Sørensen H., Hamilton-Dutoit S. Lancet Oncol. 2009, 10:825.
34. Lash T., Cronin-Fenton D., Ahern T., Rosenberg C., Lunetta K., Silliman R., Hamilton-Dutoit S., Garne J., Ewertz M., Sørensen H., Pedersen L. Acta Oncol. 2010.
35. Mihailescu R., Aboul-Enein H.Y., Efstatide M.D. Biomed. Chromatogr. 2000, 14:180.
36. Carter S.J., Li X.F., Mackey J.R., Modi S., Hanson J., Dovichi N.J. Electrophoresis 2001, 22:2730.
37. Lee K.H., Ward B.A., Desta Z., Flockhart D.A., Jones D.R. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 2003, 791:245.
38. Zhu Y.B., Zhang Q., Zou J.J., Yu C.X., Xiao D.W. J. Pharm. Biomed. Anal. 2008, 46:349.
39. Lien E.A., Ueland P.M., Solheim E., Kvinnsland S. Clin. Chem. 1987, 33:1608.
40. Esteve-Romero J., Ochoa-Aranda E., Bose D., Rambla-Alegre M., Peris-Vicente J., Martinavarro-Dominguez A. Anal. Bioanal. Chem. 2010, 397:1557.
41. Gjerde J., Kisanga E.R., Hauglid M., Holm P.I., Mellgren G., Lien E.A. J. Chromatogr. A 2005, 1082:6.
42. Teunissen S.F., Rosing H., Koornstra R.H., Linn S.C., Schellens J.H., Schinkel A.H., Beijnen J.H. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 2009, 877:2519.
43. Zweigenbaum J., Henion J. Anal. Chem. 2000, 72:2446.
44. Williams L.D., Twaddle N.C., Churchwell M.I., Doerge D.R. J. AOAC Int. 2006, 89:1168.
45. Furlanut M., Franceschi L., Pasqual E., Bacchetti S., Poz D., Giorda G., Cagol P. Ther. Drug Monit. 2007, 29:349.
46. Beer B., Schubert B., Oberguggenberger A., Meraner V., Hubalek M., Oberacher H. Anal. Bioanal. Chem. 2010, 398:1791.
47. Lien E.A., Solheim E., Kvinnsland S., Ueland P.M. Cancer Res. 1988, 48:2304.
48. Poon G.K., Chui Y.C., McCague R., Llnning P.E., Feng R., Rowlands M.G., Jarman M. Drug Metab. Dispos. 1993, 21:1119.
49. Poon G.K., Walter B., Lonning P.E., Horton M.N., McCague R. Drug Metab. Dispos. 1995, 23:377.
50. Boocock D.J., Brown K., Gibbs A.H., Sanchez E., Turteltaub K.W., White I.N. Carcinogenesis 2002, 23:1897.
51. Lim C.K., Yuan Z.X., Jones R.M., White I.N., Smith L.L. J. Pharm. Biomed. Anal. 1997, 15:1335.
52. Jones R.M., Yuan Z.X., Lamb J.H., Lim C.K. J. Chromatogr. A 1996, 722:249.
53. Mazzarino M., Fiacco I., de la Torre X., Botre F. Eur. J. Mass Spectrom. (Chichester Eng.) 2008, 14:171.
54. Mazzarino M., de la Torre X., Di Santo R., Fiacco I., Rosi F., Botre F. Rapid Commun. Mass Spectrom. 2010, 24:749.
55. FDA Homepage, Guidance for Industry: Bioanalytical Method Validation 2001, http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070107.pdf.
56. Singtoroj T., Tarning J., Annerberg A., Ashton M., Bergqvist Y., White N., Lindegardh N., Day N. J. Pharm. Biomed. Anal. 2006, 41:219.
57. Viswanathan C.T., Bansal S., Booth B., DeStefano A.J., Rose M.J., Sailstad J., Shah V.P., Skelly J.P., Swann P.G., Weiner R. Pharm. Res. 2007, 24:1962.
58. Shah V.P., Midha K.K., Findlay J.W., Hill H.M., Hulse J.D., McGilveray I.J., McKay G., Miller K.J., Patnaik R.N., Powell M.L., Tonelli A., Viswanathan C.T., Yacobi A. Pharm. Res. 2000, 17:1551.
59. Matuszewski B.K., Constanzer M.L., Chavez-Eng C.M. Anal. Chem. 2003, 75:3019.
60. Matuszewski B.K. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 2006, 830:293.
61. Crewe H.K., Notley L.M., Wunsch R.M., Lennard M.S., Gillam E.M. Drug Metab. Dispos. 2002, 30:869.
62. Zheng Y., Sun D., Sharma A.K., Chen G., Amin S., Lazarus P. Drug Metab. Dispos. 2007, 35:1942.
63. Xu R.N., Fan L., Rieser M.J., El-Shourbagy T.A. J. Pharm. Biomed. Anal. 2007, 44:342.
64. Bansal S., DeStefano A. AAPS J. 2007, 9:E109.
65. Lim C.K., Yuan Z.X., Lamb J.H., White I.N., De Matteis F., Smith L.L. Carcinogenesis 1994, 15:589.
66. Ruenitz P.C., Bagley J.R., Pape C.W. Drug Metab. Dispos. 1984, 12:478.
67. Kool J., Ramautar R., van Liempd S., Beckman J., de Kanter F., Meerman J., Schenk T., Irth H., Commandeur J., Vermeulen N. J. Med. Chem. 2006, 49:3287.